Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PIM2 encodes a protooncogene that acts as a serine/threonine protein kinase. Additionally we are shipping Proto-Oncogene Pim-2 (Serine Threonine Kinase) Proteins (13) and Proto-Oncogene Pim-2 (Serine Threonine Kinase) Kits (9) and many more products for this protein.
Showing 10 out of 102 products:
Human Polyclonal PIM2 Primary Antibody for EIA, IHC (p) - ABIN360329
Sato, Torigoe, Hirohashi, Kitamura, Tanaka, Honma, Asanuma, Harada, Takasu, Masumori, Ito, Hasegawa, Tsukamoto, Sato: Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma. in Clinical cancer research : an official journal of the American Association for Cancer Research 2008
Human Polyclonal PIM2 Primary Antibody for IHC (p), IP - ABIN392442
Pogacic, Bullock, Fedorov, Filippakopoulos, Gasser, Biondi, Meyer-Monard, Knapp, Schwaller: Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. in Cancer research 2007
Inhibition of the Pim1 (show PIM1 Antibodies) oncogene (show RAB1A Antibodies) results in diminished visual function.
We show that Pim2 inhibitors and proteasome inhibitors, such as bortezomib, have additive effects to inhibit the growth of myeloma cells, suggesting that Pim2 could be an interesting target for the treatment of multiple myeloma.
PIM2 gene knockdown enhances the anti-proliferative effect of AZD1208 in non-Hodgkin lymphoma cell line.
A high percentage of urothelial carcinomas express Pim (show PIM1 Antibodies) kinases. Pim (show PIM1 Antibodies) expression differs in NILG, NIHG, and IHG lesions.
Our findings suggest that Pim-2-mediated aerobic glycolysis is critical for monitoring Warburg effect in colorectal tumor cells, highlighting Pim-2 as a potential metabolic target for colorectal tumor therapy.
our findings will help to uncover novel signaling pathways between inflammations and oxidative stress in rheumatoid arthritis development and imply that Pim-2/mTORC1 pathway may be critical for the initiation of inflammatory reactions.
Persistent activation of STAT3 (show STAT3 Antibodies) by PIM2-driven positive feedback loop for epithelial-mesenchymal transition in breast cancer.
Data demonstrate the role of PIM (show PIM1 Antibodies) kinases in driving myeloid leukemia (show BCL11A Antibodies), and as candidate molecules for therapy against human malignancies.
Blocking the activities of PIM (show PIM1 Antibodies) kinases(PIM1 (show PIM1 Antibodies), PIM2 and PIM3 (show PIM3 Antibodies)) could prevent pancreatic cancer development. PIM (show PIM1 Antibodies) kinases(PIM1 (show PIM1 Antibodies), PIM2 and PIM3 (show PIM3 Antibodies)) may be a novel target for cancer therapy
HIF-1A (show HIF1A Antibodies) induced PIM2 expression in HepG2 cells via binding to the hypoxia-responsive elements (HREs) of the PIM2 promoter.
PIM2 could directly phosphorylate PKM2 on the Thr-454 residue, resulting in an increase of PKM2 protein levels. Compared with wild type, PKM2 with the phosphorylation-defective mutation displayed a reduced effect on glycolysis.
studies define a pathway for limiting the regulation of Foxp3 (show FOXP3 Antibodies) function because the Pim-2 kinase represents a potential therapeutic target for modulating the Treg cell suppressive activities in controlling immune responses
Pim2 facilitated allograft rejection primarily by modulating the apoptosis of effector T cells and the function of regulatory T cells.
Loss of PIM2 is associated with abnormal hematopoietic phenotypes.
signals from IL-7 (show IL7 Antibodies) and RAG DSBs activate distinct Pim (show PIM1 Antibodies) kinase family members that have context-dependent activities in regulating pre-B cell proliferation and survival.
Targeting cap-dependent translation blocks converging survival signals by AKT (show AKT1 Antibodies) and PIM 1 (show PIM1 Antibodies), 2 kinases in lymphoma
PIM2 controls the expression of the pro-inflammatory cytokine IL-6 (show IL6 Antibodies).
results support the hypothesis that Pim2, which is also a known target of Flt3 (show FLT3 Antibodies)-ITD (another gene that cooperates with PML (show PML Antibodies)-RARalpha (show RARA Antibodies)), cooperates with PRalpha to induce acute promyelocytic leukemia (show PML Antibodies)-like disease
Pim-2 is a direct link between growth factor-induced transcription and a novel, kinase-dependent pathway that promotes cell-autonomous survival
pim-2 functions similarly to pim-1 (show PIM1 Antibodies) as a pro-survival kinase; BAD is a legitimate PIM-2 substrate
Pim-2 and Akt-1 (show AKT1 Antibodies) are critical components of overlapping but independent pathways, either of which is sufficient to promote the growth and survival of nontransformed hematopoietic cells
This gene encodes a protooncogene that acts as a serine/threonine protein kinase. Studies determined the encoded protein functions to prevent apoptosis and to promote cell survival.
, proviral integration site 2
, serine/threonine-protein kinase Pim-1
, serine/threonine-protein kinase pim-2
, proto-oncogene Pim-2 (serine threonine kinase)
, serine/threonine protein kinase pim-2
, serine/threonine kinase